The Antiviral Drugs Market is predicted to reach US$ by 2030 from US$ 49 billion in 2021, and to grow at a CAGR of 3.5% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others), by Distribution Channel (Hospital, Retail, and Online Pharmacies)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
AstraZeneca plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Plc., Bristol-Myers-Squibb Company, Abbott Laboratories Inc., Schering-Plough Corporation, Merck & Co., Inc., Johnson & Johnson Services, Inc., AbbVie Inc., Cipla, Inc., Dr Reddy's Laboratories Ltd. among other
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Antiviral Drugs - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Antiviral Drugs - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Antiviral Drugs - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Antiviral Drugs - ANALYSIS & FORECAST, BY REGION
North America Antiviral Drugs
1. North America Antiviral Drugs , by Country
1. US
2. Canada
1. North America Antiviral Drugs , by Product
2. North America Antiviral Drugs , by Type
3. North America Antiviral Drugs , by Gender
4. North America Antiviral Drugs , by Sales Channel
3. Europe Antiviral Drugs
1. Europe Antiviral Drugs , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Antiviral Drugs , by Product
3. Europe Antiviral Drugs , by Type
4. Europe Antiviral Drugs , by Gender
5. Europe Antiviral Drugs , by Sales Channel
4. Asia Pacific Antiviral Drugs
1. Asia Pacific Antiviral Drugs , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Antiviral Drugs , by product
3. Asia Pacific Antiviral Drugs , by Type
4. Asia Pacific Antiviral Drugs , by Gender
5. Asia Pacific Antiviral Drugs , by Sales Channel
5. Rest of the World Antiviral Drugs
1. Rest of the World Antiviral Drugs , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Antiviral Drugs , by Product
3. Rest of the World Antiviral Drugs , by Type
4. Rest of the World Antiviral Drugs , by Gender
5. Rest of the World Antiviral Drugs , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 31